Leisure Capital Management Reduces Stock Position in GSK plc (NYSE:GSK)

Leisure Capital Management decreased its holdings in shares of GSK plc (NYSE:GSK) by 16.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,919 shares of the pharmaceutical company’s stock after selling 4,235 shares during the quarter. Leisure Capital Management’s holdings in GSK were worth $775,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Versant Capital Management Inc lifted its holdings in GSK by 2,816.7% during the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 676 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of GSK by 271.8% in the third quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 647 shares in the last quarter. BKM Wealth Management LLC bought a new position in shares of GSK in the fourth quarter valued at approximately $32,000. Jones Financial Companies Lllp grew its stake in GSK by 62.2% during the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock valued at $48,000 after acquiring an additional 509 shares in the last quarter. Finally, Princeton Global Asset Management LLC increased its holdings in GSK by 54.3% during the 4th quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after acquiring an additional 533 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on GSK shares. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Morgan Stanley started coverage on GSK in a research note on Tuesday, January 23rd. They set an “equal weight” rating for the company. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Finally, Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, GSK presently has a consensus rating of “Moderate Buy”.

GSK Price Performance

Shares of GSK stock traded up $0.20 on Friday, hitting $41.11. 2,730,464 shares of the company traded hands, compared to its average volume of 2,904,690. GSK plc has a 12-month low of $33.33 and a 12-month high of $43.84. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. The company has a market cap of $85.20 billion, a P/E ratio of 13.66, a P/E/G ratio of 1.44 and a beta of 0.64. The firm’s 50-day simple moving average is $41.83 and its 200 day simple moving average is $38.95.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The firm had revenue of $10 billion for the quarter, compared to analysts’ expectations of $9.79 billion. Analysts expect that GSK plc will post 4.03 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were given a $0.3564 dividend. This is an increase from GSK’s previous quarterly dividend of $0.34. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a $1.43 dividend on an annualized basis and a yield of 3.47%. GSK’s payout ratio is presently 52.82%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.